Politicians from across the political spectrum are up in arms over healthcare giant Sanofi’s plans to sell France’s best-known medical drug Doliprane to US investors, a move critics say would lead to a “loss of sovereignty” for the country in a sensitive industry.
Related Posts
Poppins, the French app designed to help kids with dyslexia
The 2024 Ivy Tech Prize for France’s young entrepreneur of the year was awarded on Tuesday to François Vonthron, CEO and co-founder of Poppins. The […]
US-China tech rivalry continues ahead of election
China is a top priority for US foreign and economic policy, and the trade tensions between the world’s largest economies are set to continue, regardless […]
Oil prices jump as speculation rises on possible Israeli retaliation against Iran
US crude oil jumped slightly after US President Joe Biden said he was “discussing” an Israeli strike on Iranian oil facilities. Chaos builds for shippers […]